ICAM-1-CAR Tregs

ICAM-1-CAR Tregs (also known as I1C Tregs) is a preclinical-stage chimeric antigen receptor (CAR) regulatory T cell (Treg) therapy designed to target intercellular adhesion molecule 1 (ICAM-1), an adhesion molecule and "inflammagen" that is upregulated during ischemia-reperfusion injury (IRI) and transplant rejection. Developed by researchers at Brigham and Women's Hospital and Harvard Medical School, these Tregs are engineered with a CAR containing a human LFA-1 I-domain (which binds ICAM-1) fused to CD28 and CD3ζ signaling domains. Some variants are also armored with IL-10 to modulate the immune synapse. By targeting pathological inflammation rather than donor-specific HLA antigens, ICAM-1-CAR Tregs act as a universal, HLA-agnostic cell therapy to prevent ischemia-reperfusion injury and promote graft survival in solid organ transplantation, such as heart and skin transplants.

Other names

I1C TregI-1C TregI 1C TregI1C TregsI-1C TregsI 1C TregsICAM-1-CAR TregICAM1-CAR TregICAM 1-CAR TregICAM-1-specific CAR TregICAM1-specific CAR TregICAM 1-specific CAR TregICAM-1-specific CAR TregsICAM1-specific CAR TregsICAM 1-specific CAR Tregs